Sanofi has followed in the footsteps of its rivals in the US insulin market with a 78% price cut for its most widely-used Lantus product starting next January. It will restrict out-of-pocket costs ...

We recently compiled a list of the 10 Best Foreign Stocks With Dividends For Passive Income. In this article, we are going to ...

Sanofi doesn't have many patent cliffs to worry about. Lantus now competes with biosimilars and its growth has since stalled. Plavix succumbed to generic competition years ago in the U.S., but is ...

The Odessa American is the leading source of local news, information, entertainment and sports for the Permian Basin.

Sanofi's rivals in the insulin field are nipping at its heels – Lantus sales dipped 5 per cent in the first half of 2015, and analysts don't expect Toujeo to make up for its decline.

Sanofi SNY reported fourth-quarter 2024 adjusted earnings of 70 cents per American depositary share, which missed the Zacks ...

Sanofi SA (SNY) reports robust sales growth driven by Dupixent and vaccines, while planning a significant share buyback to ...

He said that when Sanofi's senior decision-makers convene ... The pharmaceutical company, which makes drugs like Lantus insulin jabs and Plavix blood thinners, spends about three billion euros ...

GoodRx said in a statement that it is working with Sanofi to offer U.S. insulin patients a coupon for to a 30-day supply of Lantus, an insulin glargine injection and Sanofi's most widely ...

It sells products through independent distributors primarily in India.Sanofi Indias products viz. Lantus, Combiflam, Amaryl and Allegra feature in the top 100 pharmaceutical brands in India.

In 2021, the FDA approved a new insulin drug, Semglee, that was interchangeable with a brand-name insulin called Lantus.

Sanofi raised the price of Lantus from $50 a vial in 2006 to $340 in 2023. If insulin is too expensive, patients may avoid ...